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Abstract
Pregnant women are more susceptible to malaria than their non-pregnant counterparts. Less is known about the
risk of malaria in the postpartum period. The epidemiology of postpartum malaria was systematically reviewed.
Eleven articles fitted the inclusion criteria. Of the 10 studies that compared malaria data from the postpartum
period with pregnancy data, nine studies suggested that the risk for malaria infection decreased after delivery. All
three studies that compared postpartum data with non-pregnant non-postpartum women concluded that the risk
did not return to pre-pregnancy levels immediately after delivery. The results of this review have to be carefully
interpreted, as the majority of studies were not designed to study postpartum malaria, and there was large
variability in study designs and reported outcomes. Current evidence suggests an effort should be made to detect
and radically cure malaria during pregnancy so that women do not enter the postpartum period with residual
parasites.
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Background
Pregnant women are more susceptible to malaria than
their non-pregnant counterparts. This was described
nearly a century ago[1], and applies to all malaria
regions in the world, regardless of transmission intensity
[2,3]. Primigravida tend to be more susceptible than
multigravida, as women gain immunity against malaria
during successive pregnancies, particularly in areas of
high transmission[4].
To control Plasmodium falciparum malaria during
pregnancy, the WHO Roll Back Malaria recommends
several strategies: personal protection with insecticide
impregnated bed nets (ITNs), intermittent preventive
treatment (IPTp) and case management of anaemia and
malaria illness with effective anti-malarial drugs[5]. A
much less emphasized part of this recommendation is
that women in the postpartum period should be encour-
aged to use ITNs. There are no other recommended
preventive strategies for postpartum women. However,
malaria was one of the leading causes of hospital admis-
sion and maternal death among postpartum women in
Zambia[6] and India[7]. Little is known about the
epidemiology and pathophysiology of postpartum
malaria. In theory, the increased susceptibility during
pregnancy normalizes immediately after delivery when
the placenta, where the parasites can adhere during
pregnancy, is expelled. This is supported by the reports
of spontaneous clearance of P. falciparum parasites
within 24 hours after delivery in high transmission areas
in Africa[8,9]. In contrast, in Malawi[10] among women
of which some were screened at day 0, others at day 1,
2, until 1 week after delivery, the proportion with a
positive malaria blood smear was constant each day
over the first seven days (K. Msyamboza, personal com-
munication). This suggests that other factors may play a
role, such as behavioural and physiological changes that
attract mosquitoes during pregnancy[11], suppression of
cell-mediated immunity and changes in maternal hor-
monal levels. These factors take much longer to normal-
ize[12,13], and might extend beyond the usual limit of
the postpartum period which is defined by WHO as the
period until six weeks after delivery[14]. The primary
objective of this systematic review was to describe the
epidemiology of malaria in the postpartum period. This
was achieved by comparing postpartum data: 1) to long-
itudinally collected malaria data from the same women
during pregnancy; 2) to malaria data from non-pregnant,
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of residence and time; or 3) to both 1 and 2.
Methods
References for this review were identified through
searches of MEDLINE and the Malaria in Pregnancy
library[15] with the terms ‘malaria’ AND ‘postpartum’
OR ‘puerperium’ using a combination of MeSH head-
ings and keywords. The search was limited to humans,
clinical trials, in English and Spanish language until 28
February 2011. Two authors independently performed
eligibility assessment and, if disagreements were not
resolved by consensus, a decision was made by a third
author. The reporting guidance as described in the
PRISMA statement was closely followed [16].
Criteria for inclusion were: a) laboratory confirmation
of malaria in the postpartum period; b) clarity about the
timing of malaria sampling; and c) similarity in epide-
miological indicators to describe malaria in pregnant,
postpartum and control women. Exclusion criteria were:
a) selection bias e.g. only women with fever, b) seasonal
bias e.g. longitudinal cohort study with enrolment only
during one season in an area with seasonal transmission,
c) unavailability of locally comparable data (pregnant or
general population during the same time period) and d)
less than two weeks follow up after delivery. If crucial
data were missing, the authors were approached to pro-
vide additional information. Information extracted from
each study included: (1) characteristics of the study
(study subject, time period, location, enrolment criteria,
length and frequency of follow up during pregnancy and
postpartum, passive or active case detection, malaria
species, parasite densities, symptoms, methods of diag-
nosing malaria, malaria endemicity and treatment) (2)
quality of measures that could affect postpartum sus-
ceptibility (type of study, use of IPTp or chemoprophy-
laxis, samples taken during pregnancy or delivery, drug
efficacy, treatment criteria, self-treatment with anti-
malarials, use of control patients and percentage of lost
to follow up) and (3) outcome measures (incidence, pre-
valence or rate ratios of malaria infection during preg-
nancy and postpartum and in non-pregnant non
postpartum controls if available). To allow comparisons
between different studies the outcome measures of each
study were recalculated into proportions of infected
women at certain time points during pregnancy, post-
partum or in control women with confidence limits and
p-values. In studies where all women were given chemo-
prophylaxis or IPTp, only the malaria data of the first
antenatal visit were used for comparison with postpar-
tum data. When IPTp or chemoprophylaxis was used in
a randomized controlled trial, data of the placebo arm
and the study drug arm were analysed separately.
Results
The literature search provided a total of 162 abstracts of
which 128 did not meet the inclusion criteria (Figure 1).
The full text of the remaining 34 citations was examined
in detail and of these, eleven studies met the inclusion
criteria[17-27] (Figure 1). Two of these articles described
the same population but used different methodology to
detect malaria[23,25].
Characteristics of the included studies
The eleven included studies were conducted between
1968 and 2005. Only three studies were designed to
measure postpartum malaria[19,24,25]. The central
research question of the eight remaining studies per-
tained to pregnancy related subjects (Additional file 1:
T a b l eS 1 ) ,b u tt h es t u d yf o l l o w - u pw a se x t e n d e di n t o
the postpartum period for at least two months. All stu-
dies were conducted in highly endemic malarious areas:
10 studies were from Africa, where P. falciparum is the
main specie of malaria and one in Papua New Guinea
(PNG) where Plasmodium vivax is co-endemic with P.
falciparum and Plasmodium malariae. These species
were included in the analysis of the paper from PNG
[17], but the analysis in the papers from Africa was
restricted to P.falciparum, although three African stu-
dies mentioned P. malariae and/or Plasmodium ovale to
occur occasionally[22,24,26].
Quality measures of the included studies
In 10 of the 11 studies postpartum malaria was com-
pared with longitudinal data from women during preg-
nancy or at delivery (Additional file 2: Table S2). Three
of these studies compared postpartum data with non-
pregnant, non-postpartum women as well [17,19,22],
whereas one study only used the latter as a control
162 abstracts screened 
11 full text articles included 
128 abstracts did not meet inclusion criteria 
10 articles had not enough data postpartum 
2 articles had a seasonal bias  
7 articles had a selection bias (only fever included) 
2 articles had no malaria data to compare with  
1 article changed malaria detection method after delivery  
1 article was a publication of an already included cohort   
34 full text articles reviewed 
Figure 1 Schematic draft of inclusion and exclusion process.
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of each study.
The methods to describe post partum malaria varied in
epidemiological indicators between studies. Distinction
between primi- or multigravida was made in seven stu-
dies (Additional file 2: Table S2). Two studies conducted
P.falciparum genotyping on delivery samples and post-
partum samples[24,25], and sensitive detection for sub-
microscopic infection at delivery and postpartum was
performed in one study[25].
Chloroquine or sulphadoxine-pyrimethamine were used
for treatment, chemoprophylaxis or IPTp, while resistance
of P.falciparum parasites to these drugs was reported in
six of these papers (Additional file 2: Table S2). In four of
them, definitions about drug resistance were available,
either in the text or by referring to other articles
[17,23,25,26]. Self-treatment with anti-malarials was
described in two studies[19,22]. Various treatment proto-
cols of malaria episodes in pregnancy were used: in four
studies any detected parasitaemia was treated regardless of
symptoms, whereas in four other studies only women with
symptomatic infections or high parasite counts were trea-
ted with anti-malarials (Additional file 2: Table S2).
Main outcome of included studies
The pertinent points relating to postpartum susceptibil-
ity from each of the 11 manuscripts are discussed in
detail in Additional file 3. Nine of the 10 included stu-
dies that compared malaria during the postpartum per-
iod with malaria during pregnancy, showed a decline in
the proportions of malaria positive women during the
postpartum period (Figure 3, Additional file 3). The
three studies that compared postpartum data with non-
pregnant, non-postpartum controls found higher pro-
portions in postpartum women compared to controls
[19,22,24]. Of the seven studies that analysed malaria in
the postpartum period separately for different gravid-
ities, six studies observed more malaria episodes in pri-
miparous postpartum women compared to multiparous
women (RR calculated from 3 studies with proportions
available [23,25,27] = 2.77 (95% CI 1.61 - 4.77), p <
0.001). Only the study from Gabon showed a non-signif-
icant difference in risk for primiparous compared to
multiparous postpartum women (RR = 0.3 (95% CI 0.0 -
1.4), p = 0.12.)
Main outcome of studies witht IPTp or chemoprophylaxis
In two of the three studies, where weekly chloroquine
chemoprophylaxis was used during pregnancy and
stopped at delivery, an increase in malaria after delivery
was demonstrated. In PNG [17], the P. falciparum and
P. vivax incidence per person-month increased until
four months postpartum for all gravidae compared to
pregnancy, and this was significant (p = 0.002) for mul-
tiparous women with P. vivax. Proportions could not be
calculated. Also in Malawi [26], an increase in malaria
after delivery was noticed, from 289/1494 (19%) at deliv-
ery to 1430/3864 (37%), at 2 months after delivery, p <
0.001. In Gabon [24] malaria data during pregnancy
were not available and a comparison with postpartum
data could not be made.
In Mozambique [23], the IPTp arm showed a decline
in malaria proportions from 35/493 (7%) at delivery to
13/416 (3%) at two months after delivery, p = 0.004. By
PCR method [25], the proportion of infected women at
delivery was 38/187 (20%) compared to 27/138 (20%) at
8 weeks postpartum, p = 0.866.
Plasmodium falciparum genotyping and sensitive
detection
In Gabon [24], samples with PCR positive placental
infections for the merozoite surface antigen-2 (msa2)
Figure 2 Time scheme of sampling during pre-pregnancy,
pregnancy or postpartum period. M = month, D = delivery.
Open circles (○) are used for the postpartum period, filled circles (●)
for the period during pregnancy and at delivery. If the dots are
connected they represent longitudinally followed women and if
isolated they represent different groups of women.
Figure 3 Proportion of malaria positive women during
pregnancy, postpartum or in non-pregnant, non-postpartum
women. Blue represents pregnant women, red represents post
partum women and green represents non-pregnant, non-
postpartum women.
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16 puerperal malaria cases (31%, 95% CI 11-59%) carried
the same falciparum genotype as detected in the pla-
centa. In Mozambique [25], at eight weeks postpartum
50% (13/26) of women were infected with at least one
parasite strain that was present at delivery, and detected
with merozoite surface proteins (msp1 and msp2) [29].
In this study the prevalence of submicroscopic infections
in the placebo and IPTp arm combined was 21% (73/
352) at delivery and 13% (43/340) postpartum [25].
Parasite density and symptoms
Five studies (four without IPTp or chemoprophylaxis
[18-20,22], and one with chemoprophylaxis [26]) pro-
vided information about parasite densities. All reported
lower densities during the postpartum period compared
to pregnancy, two of which were significantly lower
(both p = 0.02) [19,20].
Four studies provided information about symptoms. In
the study from Senegal [19], all episodes that occurred
during pregnancy, early postpartum (first 60 days) and
in the control period were mild and rapidly cured. Few
symptomatic postpartum malaria infections (defined as
parasitaemia with a fever) were reported in the study
from Mozambique (5.1%, (2/39) [23] and Cameroon (0/
33) [20]. In Gabon [24], 61% (11/18) of malaria episodes
in the postpartum group were symptomatic, versus 17%
(1/6) in the control group. No study reported severe
malaria in the postpartum period.
Discussion
Nine of 10 reviewed studies suggested that the risk for
malaria infection during pregnancy decreased after
delivery, and one study suggests an equivalent risk after
delivery compared to pregnancy. Postpartum women
had more episodes of malaria than non-pregnant, non-
postpartum controls in the three studies that included a
control group.
However, the results of this review must be carefully
interpreted, as the majority of studies were not designed
to document specifically postpartum malaria, and there
was a large variability in study designs and outcomes.
T h eu s eo fp r e v e n t i v ed r u g si sa ne x a m p l eo fs u c ha
complicating factor: in more than half (6/11) of the stu-
dies IPTp or chemoprophylaxis were used during preg-
nancy. Chloroquine (weekly chemoprophylaxis) and
sulphadoxine-pyrimethamine (IPTp) have a long half life
and women are protected from malaria until the drug
concentration falls below the minimum inhibitory con-
centration [30]. Depending on the timing of the last
dose in pregnancy, drug half life and level of drug resis-
tance, protection could be prolonged into the early post-
partum period and may result in an underestimation of
the postpartum susceptibility to malaria when compared
to non pregnant non postpartum controls who did not
use any prevention. In Mozambique, reduced prevalence
of malaria parasitaemia at delivery and eight weeks post-
partum (detected by malaria smear) was attributed to
IPTp-sulphadoxine-pyrimethamine, though the last dose
of IPTp was given at a mean time of 77 days before
delivery [23]. This is much longer than the one-month
estimated protective effect of sulphadoxine-pyrimetha-
mine [21,30]. However, when PCR detection was used
in a selection of women from the same study [25], it
was reported that women in the IPTp group were
indeed protected from malaria at delivery, but not any-
more at eight weeks postpartum. Many post partum
women harboured sub microscopic levels of parasites.
Another effect of preventive anti-malarials during preg-
nancy was seen with use of weekly chemoprophylaxis.
In 1985 when P.vivax was still sensitive to chloroquine
in PNG, an increase in malaria incidence (P. falciparum,
but especially P. vivax) was noticed in all gravidae as
soon as the chloroquine chemoprophylaxis was stopped
at delivery [17]. Such a “rebound effect” was noticed in
a chemoprophylaxis study from Tanzania [26] as well as
in children [31]. Chemoprophylaxis may have sup-
pressed parasitaemia in pregnancy to sub-microscopic
levels, but when it was discon t i n u e da td e l i v e r y ,t h e
parasites became microscopically detectable. This is in
agreement with the recent studies, which were able to
use PCR genotyping for detection of placental and post-
partum parasites [24,25].
In the reviewed studies, postpartum women had more
malaria episodes than non-pregnant, non-postpartum
controls making plausible the existence of a transition
phase, in which the susceptibility returned to pre-preg-
nancy levels. From the data available, the length of such
a period could not be determined. In Senegal, the
increased incidence went back to pre-pregnancy levels
within 90 days after delivery [19], but in Tanzania
women still had an increased prevalence compared to
controls six months after delivery [22]. A mechanism to
explain the decreased susceptibility in the post-partum
period is maternal immunity. Fievet and colleagues
observed an impairment in the IL-2 response, and unaf-
fected or enhanced responses in IL-4 and interferon-
gamma, in 33 women from Cameroon followed during
their first pregnancy and at 6 months after delivery [20].
This was thought to favor a general depression of cellu-
lar immunity in pregnancy, rather than a specific
malaria phenomenon. The transition phase from sup-
pressed pregnancy immunity to normal pre-pregnancy
levels has also been hypothesized by others [24].
Another mechanism to explain a transition phase is the
persistence of malaria parasites from pregnancy due to
inadequate treatment. Resistance of P. falciparum to
chloroquine or sulphadoxine-pyrimethamine was
Boel et al. Malaria Journal 2012, 11:114
http://www.malariajournal.com/content/11/1/114
Page 4 of 7mentioned in 55% (6/11) of articles. Ineffective treat-
ments do not radically cure malaria infections [32], and
these infections may recrudesce in the postpartum per-
iod. The only available P.falciparum genotyping data
demonstrated that 30-50% of the postpartum infections
were persistent from delivery until the postpartum per-
iod [24,25]. Hence, highly effective treatment during
pregnancy, or IPTp regimens with highly effective drugs
would impact significantly on reducing postpartum
infection as well. In addition primiparous women have
less antibodies to the CSA binding parasites that cause
placental malaria [4] This could explain the increased
risk of post partum malaria in primiparous women com-
pared to multiparous mothers observed in six of seven
studies reviewed.
To protect the post partum mother and her neonate
[33] from malaria, an additional treatment dose of
highly effective treatment at delivery may be considered
as part of the IPTp strategy. Self-treatment may affect
the presence of parasitaemia [34], but this was only
reported in two manuscripts. Self-treatment effects are
likely to vary with the quality of the drug, the dose and
duration of treatment [35,36].
A limitation of this review is that in most published
articles microscopy was used to detect malaria, whereas
microscopy failed to detect 75% of the PCR detected
parasitaemia during the postpartum period in a recent
study [25]. The same study reports that 20 (77%) out of
the 26 women with positive placenta-paired samples had
not received treatment during labour because parasitae-
mia was sub-microscopic. The authors concluded that
such untreated sub-microscopic infections persist until
the postpartum period and reported a five-fold higher
risk (95% CI 2.49-10.63) of P. falciparum infection eight
weeks after delivery in women with sub-microscopic
placental malaria. This relation between placental and
postpartum malaria was not shown in, for example, the
study from Senegal [19], where microscopy was used.
However, at the same time, in the same area, but in the
general population, high levels of sub-patent P. falci-
parum levels (two third of microscopically negative
slides) were reported, using PCR [37]. Clearly, more
investigation is needed to determine the burden of sub-
microscopic malaria infections around delivery and in
the post partum period.
There was an increased number of symptomatic infec-
tions in the postpartum period in Senegal [19] and
Gabon [24]. Asymptomatic untreated (sub-microscopic)
infections in pregnancy may have become symptomatic
after delivery, or asymptomatic episodes were detected
and reported as symptomatic due to accompanying
fever, as women in the postpartum period are prone to
febrile co-morbidities such as mastitis and endometritis.
In both studies, the incidence of asymptomatic malaria
episodes did not increase as much as for symptomatic
episodes.
Data on non-falciparum species and the risk of post-
partum infection has only been described for PNG [17].
At least for P. vivax and P. ovale it would be very useful
to know more about the postpartum risks for infection
as primaquine, the only available drug for eradication of
the liver stage of these species, cannot be used during
pregnancy. Postpartum detection may provide a window
of opportunity for primaquine therapy so that these spe-
cies do not relapse in subsequent pregnancies.
Conclusions
Nine of 10 studies demonstrated a decreasing risk of
malaria after pregnancy, but some suggested a risk
higher than non-pregnant, non-postpartum controls. A
transition phase in which the susceptibility returns to
pre-pregnancy levels seems plausible, but from the data
available the length of this period could not be deter-
mined. Due to methodological differences in the cur-
rently available literature the results of this review have
to be carefully interpreted. Future studies that precisely
document the epidemiology and treatment of malaria
episodes during pregnancy, drug resistance, timing of
IPTp doses, and self-treatment are needed. Recommen-
dations for the design of a postpartum malaria study are
given in Additional file 4.
Sensitive detection for submicroscopic and genotyping
of parasites during pregnancy and post partum would
be an important component of future studies. The lim-
ited data available implies that efforts to detect and treat
malaria effectively during pregnancy [38] will prevent
women from entering the postpartum period with resi-
dual parasitaemia. Administration of an additional treat-
ment dose of an effective drug at delivery to all
pregnant women in endemic areas may provide some
health benefits to the mother (less anaemia), although
be of no direct consequence for the newborn, except in
reducing the risk of congenital malaria [33]. Health
workers need to be mindful that malaria acquired dur-
ing pregnancy can have consequences in the postpartum
period.
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